# DESCRIPTION

## GRANT SUPPORT

- acknowledge government grant support

## FIELD OF THE INVENTION

- introduce virus-like particles for immunogenic compositions

## BACKGROUND AND OVERVIEW OF THE INVENTION

- describe Staphylococcus aureus infections
- discuss methicillin-resistant S. aureus
- highlight limitations of antibiotics
- introduce quorum-sensing dependent virulence
- describe autoinducing peptides
- hypothesize vaccination against AIP
- summarize VLP-based vaccine approach

## BRIEF DESCRIPTION OF THE INVENTION

- introduce VLPs for SA infections
- describe AIP-VLPs and SA toxin-VLPs
- highlight prophylactic and therapeutic uses
- introduce bacteriophage single chain coat polypeptide dimer
- describe epitopic SA peptide display
- highlight AIP1 and AIP1S peptides
- discuss thiolactone group absence
- introduce AIP2, AIP2S, AIP3, AIP3S, AIP4, and AIP4S peptides
- describe VLP composition and prophylactic use
- highlight SA epitopic peptide display
- introduce hybrid VLPs
- describe VLP composition and immunotherapeutic use
- highlight SA epitopic peptide display
- introduce nucleic acid constructs
- describe bacterial or bacteriophage promoter
- highlight coat polypeptide dimer coding sequence
- introduce restriction sites
- describe antibiotic resistance gene
- highlight replication origin
- introduce PCR primer
- describe repressor to resistance
- highlight helper phage gene
- introduce second antibiotic resistance gene
- describe VLP composition and prophylactic use
- highlight SA epitopic peptide display
- introduce hybrid VLPs
- describe VLP composition and immunotherapeutic use
- highlight SA epitopic peptide display
- introduce nucleic acid constructs
- describe bacterial or bacteriophage promoter
- highlight coat polypeptide dimer coding sequence
- introduce transcription terminator

## DETAILED DESCRIPTION OF THE INVENTION

- introduce molecular biology techniques
- cite literature references
- define range of values
- define technical and scientific terms
- describe preferred methods and materials
- define singular and plural forms
- define patient or subject
- define effective amount
- define polynucleotide
- define polypeptide
- define single-chain dimer
- describe coat protein's AB-loop
- define amino acid residues
- define valency
- define coding sequence
- define heterologous region
- define origin of replication
- define promoter sequence
- define transcription termination sequences
- define expression control sequence
- define antibiotic resistance gene
- define PCR
- define PCR primer
- provide examples of primers
- define transformed cell
- define signal sequence
- describe degenerate nucleic acid sequences
- define epitope
- define coat protein
- define coat polypeptide
- define immune response
- define immunogenic
- define vaccine
- define virus-like particle of a bacteriophage
- describe VLP of RNA bacteriophage coat protein
- define operatively linked
- describe SA-induced disorders
- describe immunogenicity
- describe prophylactic efficacy
- define SA epitopic peptide
- describe Staphylococcus aureus

### Production of Virus-Like Particles

- introduce virus-like phage particles
- define in vitro and in vivo production
- describe bacteriophages
- list examples of RNA bacteriophages
- describe genome organization and replication strategy
- describe virion structure
- explain assembly of icosahedral capsid shell
- describe coat protein expression and assembly
- provide examples of PP7 coat polypeptides
- define RNA bacteriophage coat polypeptide
- explain structural similarity of coat polypeptides
- describe method for determining structural similarity
- define active coat polypeptide
- introduce SA epitopic peptide
- describe preferred presentation of SA epitopic peptide
- list examples of SA epitopic peptides
- describe truncations of SA epitopic peptides
- explain alignment of amino acid sequences
- describe preparation of transcription unit
- list components of transcription unit
- explain operable linking of components
- describe promoters and their functions
- describe synthesis of VLPs
- describe assembly of VLPs encapsidating heterologous substances
- summarize rationale for the present invention

## EXAMPLES

- present VLP-AIPs as vaccine candidates

### ADDITIONAL EXAMPLES

- describe agr operon and quorum sensing
- introduce AIP1 and its importance
- discuss limitations of AIP1 as vaccine target
- introduce VLP vaccine platform
- describe production of VLP-AIP1S vaccine
- present results of VLP-AIP1S vaccination
- show induction of AIP1-recognizing antibodies
- demonstrate efficacy of VLP-AIP1S in murine SSTI model
- show reduced agr function and virulence factor production
- discuss potential clinical utility of VLP-based vaccines
- introduce other pathogens using agr-like quorum sensing
- discuss Listeria monocytogenes agr system
- discuss Enterococcus faecalis fsr gene locus
- discuss Clostridium difficile agr locus
- highlight flexibility of VLP-based vaccine platform
- discuss FDA approval and success of VLP vaccines
- emphasize need for multi-pronged approach to combat antibiotic resistance
- highlight potential of VLP-based vaccines against bacterial pathogens

## DISCUSSION

- discuss need for non-conventional approaches to combat infectious disease
- introduce concept of inhibiting bacterial virulence
- discuss importance of agr operon in S. aureus virulence regulation
- highlight potential of VLP-based vaccine against agr type I isolates
- discuss diversity of S. aureus virulence factors
- introduce Hla as major contributor to pathogenesis
- discuss previous work on VLP-based AIP4 mimotope vaccine
- highlight potential of VLP-based approach against multiple agr types
- discuss other human pathogens using agr-like quorum sensing
- highlight potential of VLP-based vaccines against bacterial pathogens
- discuss flexibility of VLP-based vaccine platform
- emphasize need for multi-pronged approach to combat antibiotic resistance
- highlight potential clinical utility of VLP-based vaccines

## SUMMARY

- summarize results of experimentation

### Methods

- state ethics statement
- describe bacterial strains and growth conditions
- clone, express, and purify VLPs
- immunize mice
- perform ELISA
- describe mouse skin infection model
- analyze cytokine levels
- isolate RNA from tissue
- perform quantitative PCR analysis
- quantify Hla levels by Western blot
- describe statistical analysis
- detail VLP construction
- describe E. coli cell lysis and VLP purification
- determine VLP concentration
- describe serum depletion
- perform competition ELISAs
- analyze abscess and dermonecrosis areas

